Acarix AB (SE:ACARIX)
:ACARIX
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.19 - kr0.47
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.57M
Market Cap
kr310.04M
Enterprise Valuekr291.76M
Total Cash (Recent Filing)kr18.27M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr26.90M
Bulls Say, Bears Say
Bulls Say
Installed-base Recurring ConsumablesAcarix's CADScor sells capital equipment plus single-use consumables, creating recurring per-test revenue tied to each installed device. This durable business model supports predictable revenue growth per deployment and higher lifetime value as clinical adoption and testing volume scale.
Positive Gross Profit At Product LevelThe company reports positive gross margins on device and consumable sales, demonstrating viable unit economics. Positive product-level profitability means increased volume can translate to operating leverage and improved margins over time if fixed cost growth is controlled during commercialization.
Very Low Financial LeverageEffectively zero debt across recent years reduces financial distress risk and interest burden. A low-leverage balance sheet gives the company strategic flexibility to raise capital, invest in commercialization, or endure operating losses longer without immediate solvency pressure.
Bears Say
Large Operating Losses And Cash BurnAcarix is burning substantial cash relative to revenue, with FY2025 operating cash flow and EBIT near -48M versus roughly 7.4M revenue. Such persistent high burn requires frequent external financing, raises dilution risk, and undermines sustainability unless revenue growth or cost structure change materially.
Declining Equity And Shrinking Capital BaseEquity erosion from repeated losses (≈100.5M to ≈38.2M over four years) and declining assets reduce the company's financial cushion. A smaller capital base constrains investment capacity for sales, regulatory efforts, or product development and increases vulnerability to adverse events or funding squeezes.
Small Revenue Base And Limited Commercial ScaleRevenue remains modest and only recently resumed growth, limiting the firm's ability to absorb fixed costs and achieve breakeven. With commercial traction still limited, profitability depends on sustained adoption, reimbursement acceptance and broader distribution—all structural execution risks.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.19 and its highest was kr0.47 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr310.04M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is May 20, 2026 which is in 42 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Feb 12, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.649%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.